NAPLEX Quiz: Emergency Use Authorizations

What this quiz covers

This quiz focuses on Emergency Use Authorizations, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Provide reassurance and observe for an additional 10 minutes because most reactions resolve without treatment
2. Administer intramuscular epinephrine promptly, activate emergency medical services, and document/report the event per vaccine adverse event reporting requirements (correct answer)
3. Administer oral diphenhydramine only and allow the patient to drive home if symptoms improve
4. Advise the patient to return tomorrow for evaluation because reactions under EUA are not reportable

Explanation: This question tests adverse event management and reporting for vaccines under Emergency Use Authorization (EUA), focusing on anaphylaxis response. The key patient-specific factor is symptoms of throat tightness, wheezing, and hypotension suggestive of anaphylaxis in a patient with asthma and allergy history. Choice B is the best because it involves prompt epinephrine administration, activating emergency services, and reporting via VAERS, aligning with EUA safety protocols. Choice A is incorrect as observation alone is insufficient for severe reactions; Choice C is suboptimal because diphenhydramine alone does not address anaphylaxis and driving could be unsafe. Choice D is inappropriate as reactions require immediate care and are reportable under EUA. A clinical pearl is that pharmacists must be prepared with anaphylaxis kits for EUA vaccine administration sites. In EUA management, use a framework of rapid assessment, treatment, and mandatory reporting for adverse events.

Question 2

1. Dispense Paxlovid without review because ritonavir is safe with all antiretrovirals and no monitoring is needed
2. Contact the prescriber because combining Paxlovid with boosted protease inhibitor therapy may increase interaction risk; ensure an appropriate plan and counsel to avoid sildenafil during treatment due to increased exposure (correct answer)
3. Advise the patient to stop all antiretrovirals for 5 days while taking Paxlovid
4. Recommend increasing sildenafil frequency to daily to prevent COVID-19 complications

Explanation: This question examines interaction management for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA) in HIV patients. The key patient-specific factors are the boosted protease inhibitor regimen and sildenafil, both affected by ritonavir. Choice B is the best because combining boosters increases interaction risks, requiring prescriber contact and avoiding sildenafil to prevent excessive exposure per guidance. Choice A is incorrect as monitoring is needed and interactions are significant; Choice C is suboptimal as stopping antiretrovirals risks HIV resistance. Choice D is inappropriate as increasing sildenafil heightens toxicity. A clinical pearl is that ritonavir's boosting effect can compound with other inhibitors, necessitating careful review. In EUA management, develop a framework for polypharmacy assessment and alternative recommendations.

Question 3

1. Dispense the renal-adjusted dose (nirmatrelvir 150 mg with ritonavir 100 mg twice daily) because it is appropriate for any creatinine clearance below 60 mL/min
2. Hold rosuvastatin only and dispense Paxlovid at full dose because renal impairment does not change exposure
3. Do not dispense Paxlovid because it is not recommended at this level of renal impairment; contact the prescriber to discuss alternatives authorized for use (correct answer)
4. Reduce ritonavir to 50 mg twice daily and dispense nirmatrelvir 300 mg twice daily

Explanation: This question tests dosing guidance for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA) in severe renal impairment. The key patient-specific factor is estimated creatinine clearance of 18 mL/min, classifying as severe impairment. Choice C is the best because Paxlovid is not recommended in severe renal impairment due to accumulation risks, prompting prescriber contact for alternatives. Choice A is incorrect as the reduced dose is for moderate impairment only; Choice B is suboptimal because holding rosuvastatin alone does not address renal contraindication. Choice D is inappropriate as altering ritonavir alone is not evidence-based. A clinical pearl is that EUA dosing is based on pharmacokinetic studies in organ dysfunction. For EUA management, use a framework of verifying eligibility criteria like renal function before dispensing.

Question 4

1. Advise that Paxlovid will lower nifedipine levels, so he should double nifedipine while taking Paxlovid
2. Evaluate for increased nifedipine exposure due to CYP inhibition and counsel on hypotension; contact the prescriber to consider temporary dose reduction or closer monitoring during therapy (correct answer)
3. Recommend stopping bupropion immediately because it is contraindicated with Paxlovid in all patients
4. Dispense Paxlovid and advise no monitoring is needed because the course is short

Explanation: This question tests the pharmacist's knowledge of managing drug interactions with nirmatrelvir/ritonavir (Paxlovid), an antiviral authorized under Emergency Use Authorization (EUA) for mild-to-moderate COVID-19 in high-risk patients. The key patient-specific factors are the concurrent use of nifedipine, a CYP3A4 substrate, and the patient's report of lower-than-usual home blood pressures, indicating potential hypotension. Option B is the best choice because ritonavir, a strong CYP3A4 inhibitor in Paxlovid, can increase nifedipine exposure, exacerbating hypotension, so evaluating this interaction, counseling the patient, and contacting the prescriber for dose adjustment or monitoring ensures safe EUA medication use. Option A is incorrect because Paxlovid increases, rather than decreases, nifedipine levels due to CYP3A4 inhibition, making dose doubling inappropriate and risky. Option C is suboptimal as bupropion is not contraindicated with Paxlovid; while ritonavir may affect bupropion levels via CYP2B6 induction, abrupt cessation is unnecessary without clinical indication, and the primary concern here is nifedipine. Option D is inappropriate because the short course does not negate the need for monitoring serious interactions like this one, which could lead to adverse events. A key clinical pearl is to always consult the Paxlovid EUA fact sheet for interaction management, prioritizing prescriber communication for adjustments in patients with comorbidities. When handling EUA drugs, pharmacists should use a systematic framework: identify potential interactions via CYP pathways, assess patient-specific risks, and collaborate interprofessionally to optimize therapy while minimizing harm.

Question 5

1. Counsel that molnupiravir is preferred in pregnancy because it has extensive fetal safety data
2. Advise that molnupiravir is not recommended in pregnancy due to potential fetal risk; contact the prescriber to discuss alternative therapy and document counseling per EUA fact sheet (correct answer)
3. Recommend doubling the dose to ensure adequate placental transfer
4. Advise that EUA status means pregnancy warnings do not apply

Explanation: This question assesses counseling for molnupiravir under Emergency Use Authorization (EUA) in pregnancy. The key patient-specific factor is early pregnancy (10 weeks gestation), where fetal risks are a concern. Choice B is the best because molnupiravir has potential embryo-fetal toxicity, making it not recommended in pregnancy, with prescriber discussion of alternatives and documentation per EUA. Choice A is incorrect as molnupiravir lacks extensive safety data and is not preferred; Choice C is suboptimal as doubling risks harm without benefit. Choice D is inappropriate as EUA status does not negate pregnancy warnings. A clinical pearl is that reproductive toxicity data from animal studies guide EUA counseling in pregnancy. For EUA management, apply a framework of assessing reproductive status and discussing contraception requirements.

Question 6

1. Advise no changes because inhaled corticosteroids cannot interact with ritonavir
2. Assess for interaction risk because ritonavir can increase systemic corticosteroid exposure; contact the prescriber to consider an alternative inhaled steroid or monitoring for adrenal suppression/Cushingoid effects (correct answer)
3. Recommend increasing fluticasone/salmeterol to four times daily during Paxlovid therapy
4. Stop metformin immediately because ritonavir causes severe lactic acidosis in all patients

Explanation: This question assesses interaction management for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA) with inhaled corticosteroids. The key patient-specific factor is fluticasone use, which can have increased systemic exposure via CYP3A4 inhibition. Choice B is the best because ritonavir elevates corticosteroid levels, risking adrenal suppression, requiring prescriber contact for alternatives or monitoring. Choice A is incorrect as inhaled steroids can interact systemically; Choice C is suboptimal as increasing the dose heightens risks. Choice D is inappropriate as ritonavir does not cause lactic acidosis with metformin. A clinical pearl is that even inhaled drugs can have significant interactions with strong CYP inhibitors. For EUA management, employ a framework of comprehensive medication review and symptom monitoring.

Question 7

1. Dispense Paxlovid as written and counsel that interactions are unlikely because the course is only 5 days
2. Recommend holding atorvastatin during Paxlovid therapy and for several days after, and contact the prescriber to assess apixaban management due to ritonavir increasing anticoagulant exposure (correct answer)
3. Increase atorvastatin to 80 mg nightly during Paxlovid therapy to reduce COVID-19 complications
4. Switch apixaban to rivaroxaban without prescriber involvement because both are direct oral anticoagulants

Explanation: This question evaluates drug interaction management for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA), emphasizing CYP3A4 inhibition effects. The key patient-specific factors are concomitant use of atorvastatin and apixaban, both CYP3A4 substrates, in a patient with chronic kidney disease and atrial fibrillation. Choice B is the best because it recommends holding atorvastatin to avoid myopathy and consulting the prescriber for apixaban management due to increased bleeding risk from elevated exposure, following EUA interaction guidance. Choice A is incorrect as even short courses can cause significant interactions; Choice C is suboptimal because increasing atorvastatin heightens toxicity risk without benefit. Choice D is inappropriate as switching anticoagulants requires prescriber involvement and may not resolve the interaction. A clinical pearl is to use interaction checkers and EUA fact sheets to identify and mitigate risks with ritonavir-boosted therapies. In EUA management, develop a framework of screening for interactions, consulting prescribers, and counseling on temporary medication holds.

Question 8

1. Counsel that the vaccine contains live attenuated virus and he should avoid contact with immunocompromised people for 2 weeks
2. Counsel that the vaccine does not contain live SARS-CoV-2 virus and does not cause infection, and provide the EUA fact sheet with expected adverse effects and when to seek care (correct answer)
3. Advise that EUA vaccines cannot be discussed because efficacy data are confidential
4. Recommend taking antibiotics after vaccination to prevent viral shedding

Explanation: This question examines counseling for COVID-19 vaccines under Emergency Use Authorization (EUA), addressing misconceptions about viral content. The key patient-specific factor is the patient's concern about live virus and shedding in a healthy individual. Choice B is the best because mRNA vaccines do not contain live virus, cannot cause infection, and the EUA fact sheet provides accurate information on effects. Choice A is incorrect as COVID-19 vaccines are not live attenuated; Choice C is suboptimal as efficacy data are public under EUA. Choice D is inappropriate as antibiotics do not prevent viral issues. A clinical pearl is that vaccine counseling should dispel myths to improve uptake. For EUA management, use a framework of fact-based education and resource provision.

Question 9

1. Dispense Paxlovid and advise no changes because ritonavir has minimal effect on CYP enzymes
2. Contact the prescriber because ritonavir can increase tofacitinib exposure; recommend holding or dose-reducing tofacitinib during Paxlovid per interaction guidance (correct answer)
3. Increase tofacitinib to 10 mg twice daily during Paxlovid therapy to maintain rheumatoid arthritis control
4. Stop omeprazole because it will inactivate Paxlovid in the stomach

Explanation: This question evaluates interaction management for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA) with immunosuppressants. The key patient-specific factor is tofacitinib use, a CYP3A4 substrate, in a rheumatoid arthritis patient. Choice B is the best because ritonavir increases tofacitinib exposure, requiring prescriber contact for holding or dose reduction per EUA guidance. Choice A is incorrect as ritonavir strongly affects CYP enzymes; Choice C is suboptimal as increasing tofacitinib risks toxicity. Choice D is inappropriate as omeprazole does not inactivate Paxlovid. A clinical pearl is to prioritize interaction severity, with strong inhibitors like ritonavir often necessitating adjustments. In EUA management, use a framework of prescriber collaboration and patient counseling on interaction risks.

Question 10

1. Serum sodium every 12 hours to detect hyponatremia
2. Hepatic enzymes (ALT/AST) during therapy and assess for worsening liver inflammation (correct answer)
3. Serum amylase daily to detect pancreatitis
4. Hemoglobin A1c weekly to detect hyperglycemia

Explanation: This question tests safety monitoring for remdesivir under Emergency Use Authorization (EUA) in liver disease. The key patient-specific factor is elevated ALT/AST in a chronic hepatitis B patient. Choice B is the best because remdesivir can worsen hepatic inflammation, requiring enzyme monitoring during therapy. Choice A is incorrect as hyponatremia is not a key risk; Choice C is suboptimal since pancreatitis is not common. Choice D is inappropriate as hyperglycemia monitoring is not primary for remdesivir. A clinical pearl is to monitor liver function closely in patients with pre-existing hepatic conditions. For EUA management, use a framework of baseline and serial labs for high-risk organs.

Question 11

1. Absolute neutrophil count daily to detect agranulocytosis
2. International normalized ratio (INR) daily to detect over-anticoagulation
3. Hepatic function (ALT/AST) prior to and during therapy due to risk of transaminase elevations (correct answer)
4. Serum potassium every 6 hours due to high risk of hyperkalemia

Explanation: This question assesses safety monitoring for remdesivir under Emergency Use Authorization (EUA), focusing on hepatic risks in vulnerable patients. The key patient-specific factor is elevated baseline ALT/AST in a patient with nonalcoholic fatty liver disease. Choice C is the best because remdesivir can cause transaminase elevations, necessitating hepatic function monitoring before and during therapy to detect hepatotoxicity early. Choice A is incorrect as agranulocytosis is not a primary remdesivir risk; Choice B is suboptimal since remdesivir does not significantly affect coagulation. Choice D is inappropriate as hyperkalemia is not a common adverse effect requiring such frequent monitoring. A clinical pearl is that EUA antiviral monitoring should align with known toxicities, like hepatotoxicity for remdesivir. For EUA management, establish a decision framework of baseline and ongoing lab assessments tailored to patient comorbidities.

Question 12

1. Counsel to take Paxlovid only when symptoms are severe and stop once he feels better, regardless of remaining tablets
2. Counsel to start as soon as possible within the authorized time window after symptom onset, take it exactly as prescribed for 5 days, and review the EUA fact sheet including what to do for missed doses (correct answer)
3. Counsel that because it is under EUA, dosing is flexible and can be taken once daily to reduce side effects
4. Advise to crush the tablets and mix with grapefruit juice to improve absorption

Explanation: This question examines administration counseling for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA). The key patient-specific factor is the need for timely initiation and adherence in a renal impairment patient. Choice B is the best because it emphasizes starting within the EUA-authorized window, completing the full 5-day course, and reviewing the fact sheet for missed doses. Choice A is incorrect as therapy should be completed regardless of symptoms; Choice C is suboptimal as dosing is not flexible under EUA. Choice D is inappropriate as crushing and mixing with grapefruit juice is not recommended. A clinical pearl is that antiviral efficacy depends on adherence to the full regimen. For EUA management, use a framework of timing, adherence, and resource-based counseling.

Question 13

1. Advise that Paxlovid will decrease tamsulosin levels, so he should take two capsules daily
2. Assess for increased tamsulosin exposure due to CYP inhibition and counsel on orthostatic hypotension risk; contact the prescriber to consider holding or adjusting tamsulosin during treatment (correct answer)
3. Recommend adding sildenafil daily to prevent dizziness
4. Dispense Paxlovid and advise no counseling is needed because EUA products do not require interaction screening

Explanation: This question evaluates interaction management for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA) with alpha-blockers. The key patient-specific factor is tamsulosin use, potentially leading to increased exposure and orthostatic hypotension. Choice B is the best because assessing and adjusting tamsulosin mitigates risks, with prescriber contact and counseling on symptoms. Choice A is incorrect as ritonavir increases, not decreases, levels; Choice C is suboptimal as adding sildenafil could worsen hypotension. Choice D is inappropriate as interaction screening is required for EUA products. A clinical pearl is that alpha-blockers can have amplified effects with CYP inhibitors. For EUA management, use a framework of symptom-based counseling and dose adjustments.

Question 14

1. Immediately discontinue all future COVID-19 treatments permanently because any reaction means absolute contraindication to all therapies
2. Recommend pausing the infusion, assessing severity, treating per protocol (e.g., antihistamine/bronchodilator if needed), and ensuring documentation and reporting consistent with EUA requirements (correct answer)
3. Continue the infusion at a faster rate to finish sooner and reduce symptoms
4. Advise giving oral ibuprofen only and ignore documentation because EUA therapies do not require adverse event reporting

Explanation: This question tests adverse reaction management for EUA infusion therapies like monoclonal antibodies. The key patient-specific factor is mild infusion-related symptoms (flushing, pruritus, shortness of breath) during administration. Choice B is the best because pausing, assessing, treating appropriately, and reporting per EUA requirements ensures safety and compliance. Choice A is incorrect as discontinuation is not permanent for all therapies; Choice C is suboptimal as speeding the infusion could worsen reactions. Choice D is inappropriate as ibuprofen alone is insufficient and reporting is mandatory. A clinical pearl is that most infusion reactions are manageable with protocol-based interventions. For EUA management, use a framework of severity assessment, treatment, and documentation.

Question 15

1. Dispense Paxlovid because carbamazepine will increase antiviral levels and improve efficacy
2. Do not dispense Paxlovid and contact the prescriber because carbamazepine is a strong inducer that can reduce Paxlovid effectiveness and may be contraindicated; discuss alternative COVID-19 therapy (correct answer)
3. Reduce carbamazepine to 200 mg twice daily for 5 days and dispense Paxlovid without notifying the prescriber
4. Advise the patient to stop oral contraception because it will increase Paxlovid toxicity

Explanation: This question tests interaction management for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA) with enzyme inducers. The key patient-specific factor is carbamazepine, a strong CYP3A4 inducer, potentially reducing Paxlovid efficacy. Choice B is the best because inducers like carbamazepine are contraindicated with Paxlovid, requiring prescriber contact for alternatives. Choice A is incorrect as induction decreases levels, not increases; Choice C is suboptimal as adjusting without prescriber input is unsafe. Choice D is inappropriate as oral contraceptives do not increase Paxlovid toxicity. A clinical pearl is that strong inducers can render antivirals ineffective, necessitating avoidance. For EUA management, develop a framework for contraindication screening and alternative therapy selection.

Question 16

1. Counsel that because it is under EUA, the product has unknown risks and the patient must sign a legal waiver before receiving it
2. Counsel on potential infusion-related reactions, the need to seek care for hypersensitivity symptoms, and provide the EUA fact sheet describing benefits, risks, and alternatives (correct answer)
3. Advise that the medication eliminates the need for isolation because it prevents transmission immediately
4. Recommend taking the medication by mouth with food to reduce infusion reactions

Explanation: This question evaluates patient counseling for monoclonal antibodies under Emergency Use Authorization (EUA), focusing on administration and risks. The key patient-specific factor is the intravenous infusion route and potential for hypersensitivity in a patient with comorbidities. Choice B is the best because it addresses infusion-related reactions, symptoms to watch, and provides the EUA fact sheet on benefits/risks/alternatives. Choice A is incorrect as no legal waiver is required; Choice C is suboptimal as treatment does not eliminate transmission risk. Choice D is inappropriate as monoclonal antibodies are not oral. A clinical pearl is that EUA monoclonal antibodies require monitoring during and post-infusion for reactions. In EUA management, apply a framework of route-specific counseling and adverse effect education.

Question 17

1. Dispense Paxlovid and rivaroxaban together without changes because direct oral anticoagulants do not interact with CYP inhibitors
2. Contact the prescriber because ritonavir can increase rivaroxaban exposure and bleeding risk; recommend an alternative COVID-19 therapy or anticoagulation strategy per guidance (correct answer)
3. Double the rivaroxaban dose during Paxlovid therapy to prevent thrombosis from COVID-19
4. Advise the patient to stop rivaroxaban for 2 weeks without prescriber involvement

Explanation: This question evaluates interaction management for nirmatrelvir/ritonavir (Paxlovid) under Emergency Use Authorization (EUA) with anticoagulants. The key patient-specific factor is rivaroxaban use, a CYP3A4 and P-gp substrate, increasing bleeding risk with ritonavir. Choice B is the best because it recommends prescriber contact to adjust anticoagulation or choose alternative COVID-19 therapy per guidance. Choice A is incorrect as direct oral anticoagulants do interact with CYP inhibitors; Choice C is suboptimal as doubling rivaroxaban exacerbates bleeding risk. Choice D is inappropriate as stopping without oversight risks thrombosis. A clinical pearl is to consider bleeding risk in COVID-19 patients on anticoagulants with inhibitors. In EUA management, use a framework of risk-benefit assessment and prescriber collaboration.

Question 18

1. Provide the FDA-required patient fact sheet, explain benefits/risks and alternatives, and document counseling consistent with EUA conditions of authorization (correct answer)
2. Tell the patient that no written information is permitted because the product is not FDA-approved
3. Explain that EUA products are identical to over-the-counter medications and require no counseling
4. State that only the prescriber may discuss risks and benefits, and the pharmacist should not answer questions about EUA status

Explanation: This question explores the pharmacist's role in patient education for oral antivirals under Emergency Use Authorization (EUA), including provision of fact sheets. The key patient-specific factor is the patient's inquiry about EUA meaning and required information in a high-risk individual. Choice A is the best because it mandates providing the FDA fact sheet, explaining benefits/risks/alternatives, and documenting, fulfilling EUA conditions. Choice B is incorrect as written information is required; Choice C is suboptimal because EUA products differ from OTC and need specific counseling. Choice D is inappropriate as pharmacists are key in discussing EUA details. A clinical pearl is that EUA allows use based on available data during emergencies, not full approval. For EUA management, employ a framework of standardized counseling and documentation to ensure compliance and patient understanding.

Question 19

1. Advise her that EUA products are experimental and cannot be refused once offered by the pharmacy
2. Screen for contraindications such as a known severe allergy to a vaccine component (e.g., PEG) and explain the option to accept or refuse an EUA product (correct answer)
3. Reassure her that EUA vaccines have the same approval standards as fully FDA-approved products, so allergy history is not relevant
4. Recommend premedication with diphenhydramine and proceed with vaccination despite prior anaphylaxis to PEG

Explanation: This question tests patient counseling principles for vaccines under Emergency Use Authorization (EUA), focusing on informed consent, the right to refuse, and screening for contraindications. The key patient-specific factor is the history of anaphylaxis to polyethylene glycol (PEG), which is a component in certain COVID-19 vaccines like mRNA-based ones. Choice B is the best option because it ensures safety by screening for contraindications such as severe allergies and educates the patient on their right to accept or refuse the EUA product, aligning with FDA requirements for voluntary administration. Choice A is incorrect as EUA products are not mandatory and patients can refuse them; Choice C is suboptimal because EUA products have expedited review but not full approval, and allergies remain critical. Choice D is inappropriate as it suggests proceeding despite a contraindication, risking anaphylaxis, and premedication alone may not mitigate severe reactions. A transferable clinical pearl is that pharmacists must provide EUA fact sheets detailing benefits, risks, and alternatives to support informed decisions. When managing EUA medications, always prioritize patient autonomy by clearly explaining options and documenting counseling.

Question 20

1. ALT and AST during therapy to monitor for hepatotoxicity (correct answer)
2. Serum digoxin level to prevent toxicity
3. Thyroid-stimulating hormone weekly
4. Serum magnesium every 4 hours due to torsades de pointes risk

Explanation: This question assesses safety monitoring for remdesivir under Emergency Use Authorization (EUA), emphasizing hepatic effects. The key patient-specific factor is baseline ALT in a heart failure patient with renal impairment. Choice A is the best because remdesivir can cause hepatotoxicity, requiring ALT/AST monitoring to detect elevations. Choice B is incorrect as digoxin toxicity is not a remdesivir concern; Choice C is suboptimal since thyroid effects are not primary. Choice D is inappropriate as magnesium monitoring is not routinely needed for torsades risk with remdesivir. A clinical pearl is that hepatic monitoring is crucial for antivirals with liver metabolism. In EUA management, apply a framework of toxicity-specific labs based on patient comorbidities.